Here, we report six novel, easily accessible BODIPY-based
agents
for cancer treatment. In contrast to established photodynamic therapy
(PDT) agents, these BODIPY-based compounds show additional photothermal
activity and their cytotoxicity is not dependent on the generation
of reactive oxygen species (ROS). The agents show high photocytotoxicity
upon irradiation with light and low dark toxicity in different cancer
cell lines in 2D culture as well as in 3D multicellular tumor spheroids
(MCTSs). The ratio of dark to light toxicity (phototoxic index, PI)
of these agents reaches striking values exceeding 830,000 after irradiation
with energetically low doses of light at 630 nm. The oxygen-dependent
mechanism of action (MOA) of established photosensitizers (PSs) hampers
effective clinical deployment of these agents. Under hypoxic conditions
(0.2% O2), which are known to limit the efficiency of conventional
PSs in solid tumors, photocytotoxicity was induced at the same concentration
levels, indicating an oxygen-independent photothermal MOA. With a
PI exceeding 360,000 under hypoxic conditions, both PI values are
the highest reported to date. We anticipate that small molecule agents
with a photothermal MOA, such as the BODIPY-based compounds reported
in this work, may overcome this barrier and provide a new avenue to
cancer therapy.
Here we report six novel, easily accessible BODIPY‐based agents for cancer treatment. In contrast to established photodynamic therapy (PDT) agents, these BODIPY-based compounds show additional photothermal activity and their cytotoxicity is not dependent on the generation of reactive oxygen species (ROS). The agents show high photocytotoxicity upon irradiation with light and low dark toxicity in different cancer cell lines in 2D culture as well as in 3D multicellular tumour spheroids (MCTSs). The ratio of dark to light toxicity (phototoxic index, PI) of these agents reaches striking values exceeding 830ʹ000 after irradiation with energetically low doses of light at 630 nm. The oxygen‐dependent mechanism of action (MOA) of established photosensitizers (PSs) hampers effective clinical deployment of these agents. Under hypoxic conditions (0.2% O2), which are known to limit the efficiency of conventional PSs in solid tumours, a PI of 360ʹ000 was observed, indicating an oxygen-independent photothermal MOA. Both PI values are the highest reported to date. We anticipate that small molecule agents with a photothermal MOA, such as BODIPY-based compounds, may overcome this barrier and provide a new avenue to cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.